Where do Enliven Therapeutics's ratios come from?

Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Returns
Return on equity	-26.6%+0.3pp	-27%-1.5pp	-25.4%-0.2pp	-25.3%+6.0pp	-31.3%+0.7pp
Return on assets	-25.7%+0.1pp	-25.9%-1.4pp	-24.4%-0.3pp	-24.1%+5.3pp	-29.4%+0.4pp
Return on invested capital	-45.5%—	——	-39.9%-0.4pp	-39.5%+22.4pp	-61.9%—
Liquidity
Current ratio	40.3×+11.7×	28.7×-4.3×	32.9×+0.4×	32.6×+11.5×	21.1×+1.1×
Quick ratio	40.3×+11.7×	28.7×-4.3×	32.9×+0.4×	32.6×+11.5×	21.1×+1.1×
Cash ratio	11.5×+5.5×	6×-1.0×	6.9×-0.9×	7.9×+0.6×	7.3×-0.5×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×—
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×—
Interest coverage	-6.8×+0.7×	-7.5×0.0×	-7.4×+0.7×	-8.2×-0.7×	-7.4×-0.4×
Per Share
Book value per share	$7.22-11.0%	$8.11+5.8%	$7.67-18.2%	$9.37+62.8%	$5.76-12.5%
Valuation
Market capitalization	$2.34B+156%	$913.95M-24.6%	$1.21B-2.9%	$1.25B+29.4%	$964.41M-12.3%
Enterprise value	$2.21B+171%	$815.45M-26.6%	$1.11B-1.6%	$1.13B+30.8%	$863.4M—
Price / book	5.2×+3.2×	2×-0.6×	2.5×0.0×	2.6×-0.8×	3.3×-0.2×
Free cash flow yield	-2.8%+4.9pp	-7.7%-1.8pp	-5.9%-0.3pp	-5.7%+2.0pp	-7.7%-1.0pp
Earnings yield	-4.2%+7.1pp	-11.3%-3.3pp	-8%0.0pp	-8%+1.8pp	-9.8%-1.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Enliven Therapeutics's ratios come from?: Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.